AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 9007770
Drug: Short CPM
RxNorm normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short CPM duration with CPM ROM increased daily to patient tolerance
Trial: 9007770
Drug: Long CPM
RxNorm normalized name: long pepper extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long CPM duration (10-12 hours per day) with CPM ROM increased 5 degrees twice daily
Trial: 9007770
Drug: Long CPM
RxNorm normalized name: long pepper extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long CPM duration with CPM ROM increased daily to patient tolerance
Trial: 8110435
Drug: Calcium supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium supplementation (1.5 g/day) for 8 weeks
Trial: 27678295
Drug: Vigil (1.0×10^7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vigil (1.0×10^7 cells/intradermal injection/month for 4 to 12 doses)
Trial: 19940012
Drug: Axitinib (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Axitinib (5 mg twice daily) with FOLFOX plus 5 mg/kg bevacizumab
Trial: 19940012
Drug: Axitinib (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Axitinib (5 mg twice daily) with FOLFOX plus 2 mg/kg bevacizumab
Trial: 19940012
Drug: Axitinib (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Axitinib (5 mg twice daily) with FOLFIRI
Trial: 19940012
Drug: Axitinib (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Axitinib (5 mg twice daily) with FOLFOX
Trial: 18981327
Drug: Candesartan (16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candesartan (16 to 32 mg)
Trial: 18981327
Drug: Hydrochlorothiazide (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (25 to 50 mg)
Trial: 12166578
Drug: Continuous oxygen
RxNorm normalized name: Uniphyllin Continus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous oxygen therapy (COT) > or = 15 h daily
Trial: 12166578
Drug: Noncontinuous oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Noncontinuous oxygen therapy (NCOT) <15 h daily
Trial: 25467591
Drug: Grazoprevir (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grazoprevir (100 mg daily) and Elbasvir (50 mg daily) with ribavirin for 12 weeks
Trial: 25467591
Drug: Grazoprevir (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grazoprevir (100 mg daily) and Elbasvir (50 mg daily) with ribavirin for 18 weeks
Trial: 25467591
Drug: Grazoprevir (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grazoprevir (100 mg daily) and Elbasvir (50 mg daily) without ribavirin for 12 weeks
Trial: 7868711
Drug: 250 mg/day
RxNorm normalized name: alpelisib 250 mg/day (200 mg x 1 and 50 mg x 1) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg/day terbinafine
Trial: 21103938
Drug: 100 mg/day
RxNorm normalized name: infigratinib phosphate 100 mg/day (100 mg x 1) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg/day itraconazole
Trial: 17080254
Drug: L-acetylcarnitine (LAC),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-acetylcarnitine (LAC), n=13
Trial: 11711355
Drug: Abarelix 100
RxNorm normalized name: abarelix 100 mg INTRAMUSC VIAL (EA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abarelix 100 mg
Trial: 7957455
Drug: microencapsulated potassium
RxNorm normalized name: Microencapsulated potassium chloride 15 MEQ Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: microencapsulated potassium chloride tablet (MET)
Trial: 7957455
Drug: potassium chloride
RxNorm normalized name: Potassium Chloride
DrugBank: Potassium chloride (DB00761)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: potassium chloride solution (PS)
Trial: 7957455
Drug: microencapsulated potassium
RxNorm normalized name: Microencapsulated potassium chloride 15 MEQ Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: microencapsulated potassium chloride capsules (MEC)
Trial: 28327694
Drug: SurfLink-treated titanium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SurfLink-treated titanium dental implants
Trial: 28327694
Drug: Untreated control
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Untreated control titanium dental implants
Trial: 22008390
Drug: High-dose UFH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose UFH (100 units kg(‐1) bolus, followed by 20 units kg h(‐1) continuous infusion)
Trial: 22008390
Drug: Low-dose UFH
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose UFH (50 units kg(‐1) bolus)
Trial: 22008390
Drug: High-dose UFH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose UFH
Trial: 22008390
Drug: Low-dose UFH
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose UFH
Trial: 19428087
Drug: Pelvic plexus
RxNorm normalized name: Bos taurus solar plexus preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pelvic plexus block with 2 mL of 2% lidocaine
Trial: 19428087
Drug: Periprostatic nerve
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Periprostatic nerve block (PPNB) with 2 mL of 2% lidocaine
Trial: 16716214
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose aspirin (100 mg daily for 5 days)
Trial: 16716214
Drug: Medium dose
RxNorm normalized name: TRIGLYCERIDES,MEDIUM CHAIN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium dose aspirin (325 mg daily for 5 days)
Trial: 16716214
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose aspirin vs Medium dose aspirin
Trial: 9389342
Drug: ASTED system
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASTED system for sample preparation prior to HPLC
Trial: 7906473
Drug: Topical betaxolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical betaxolol (0.5%) administered 5-6 hours before surgery
Trial: 7906473
Drug: Topical betaxolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical betaxolol (0.5%) administered 12 hours before surgery
Trial: 7906473
Drug: Topical betaxolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical betaxolol (0.5%) administered 24 hours before surgery
Trial: 7906473
Drug: Topical betaxolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical betaxolol (0.5%) administered 48 hours before surgery
Trial: 7906473
Drug: Topical betaxolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical betaxolol (0.5%) administered 4 hours before surgery into the contralateral eye
Trial: 2886529
Drug: One dose
RxNorm normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: One dose of 500 mg metronidazole
Trial: 2886529
Drug: Zero, two,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zero, two, three, six, or twenty-one doses of metronidazole
Trial: 25421542
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid administered once during preoperative hormonal therapy with letrozole for 24 weeks
Trial: 22401913
Drug: Oral conjugated
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral conjugated equine oestrogen (0.625 mg per day)
Trial: 20885291
Drug: Scvo2-guided fluid
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scvo2-guided fluid therapy (crystalloid infusion 100 ml/h, bolus of 3 ml/kg hydroxyethyl starch if Scvo2 < 75%)
Trial: 20885291
Drug: Traditional fluid
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional fluid regimen (crystalloid 800 ml/h, extra fluid for clinical signs of hypovolemia)
Trial: 17138193
Drug: Radial nerve
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radial nerve injection (group RAD)
Trial: 17138193
Drug: Ulnar nerve
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ulnar nerve injection (group ULN)
Trial: 14732882
Drug: Biochemotherapy regimens
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biochemotherapy regimens combining IL‐2, IFN‐alpha and chemotherapy
Trial: 14732882
Drug: Cytokines alone
RxNorm normalized name: cytosine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cytokines alone (IL‐2 as a single agent or in combination with IFN‐alpha)
Trial: 14732882
Drug: Immunotherapy alone
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunotherapy alone with additions (histamine or vaccines to IL‐2)
Trial: 10761967
Drug: 3-g ginseng
RxNorm normalized name: PANAX GINSENG WHOLE 0.3 g ORAL CAPSULE [Mirapharm-22]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-g ginseng taken 40 minutes before glucose challenge
Trial: 10761967
Drug: 3-g ginseng
RxNorm normalized name: PANAX GINSENG WHOLE 0.3 g ORAL CAPSULE [Mirapharm-22]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-g ginseng taken together with glucose challenge
Trial: 10761967
Drug: 3-g ginseng
RxNorm normalized name: PANAX GINSENG WHOLE 0.3 g ORAL CAPSULE [Mirapharm-22]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-g ginseng taken before glucose challenge
Trial: 8672407
Drug: Fat-replaced meal
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fat-replaced meal (3305 kJ, 54.6 g SPE, 24 g fat)
Trial: 8672407
Drug: Control meal
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control meal (5192 kJ, 73.2 g fat)
Trial: 1599343
Drug: Nonpharmacologic intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nonpharmacologic intervention (weight reduction, sodium restriction, increased physical activity) consisting of eight weekly group sessions and two individual sessions followed by four monthly group sessions.
Trial: 6532149
Drug: Response prevention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Response prevention treatment
Trial: 6532149
Drug: Rapid smoking
RxNorm normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapid smoking comparison treatment
Trial: 30616899
Drug: Coaching care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coaching care (CC) with weekly phone calls for 3 months
Trial: 24786935
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (self-administered)
Trial: 22462640
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D deficiency (25(OH)D < 50 nmol/l) at 24-26 weeks of gestation
Trial: 8878218
Drug: 5 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 micrograms Engerix-B vaccine
Trial: 8878218
Drug: 10 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 micrograms Engerix-B vaccine
Trial: 2049750
Drug: Tamoxifen (TAM)
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tamoxifen (TAM) plus prednisolone (PRDLN) (5 mg twice daily)
Trial: 2049750
Drug: Tamoxifen (TAM)
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tamoxifen (TAM) (10 mg twice daily) plus placebo
Trial: 30723140
Drug: Letrozole plus
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Letrozole plus Alpelisib (2.5 mg/day letrozole with 300 mg/day alpelisib for 24 weeks)
Trial: 17931925
Drug: 1.8 mL
RxNorm normalized name: insulin pump syringe, 1.8 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.8 mL 0.5% bupivacaine with 1:200,000 epinephrine
Trial: 17931925
Drug: 1.8 mL
RxNorm normalized name: insulin pump syringe, 1.8 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.8 mL 2% lidocaine with 1:100,000 epinephrine
Trial: 9462439
Drug: Cefuroxime 750
RxNorm normalized name: cefuroxime 750 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefuroxime 750 mg iv tds for 48-72 h followed by oral cefuroxime axetil 500 mg bd for 5-7 days
Trial: 9462439
Drug: Cefuroxime 750
RxNorm normalized name: cefuroxime 750 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefuroxime 750 mg iv bd for 48-72 h followed by oral cefuroxime axetil 500 mg bd for 5-7 days
Trial: 8170877
Drug: Intravenous heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous heparin and nitroglycerin (GTN) at a constant dose of 16.6 micrograms/minute
Trial: 8170877
Drug: Intravenous heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous heparin and isosorbide dinitrate at a constant dose of 33.3 micrograms/minute
Trial: 8170877
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups received identical doses of heparin
Trial: 29474893
Drug: Personalized bronchodilator
RxNorm normalized name: Bronchodil
DrugBank: Reproterol (DB12846)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Personalized bronchodilator dosing
Trial: 29474893
Drug: Fixed bronchodilator
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed bronchodilator dosing
Trial: 21397720
Drug: HBV vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HBV vaccine with GM-CSF
Trial: 21397720
Drug: HBV vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HBV vaccine without GM-CSF
Trial: 21397720
Drug: GM-CSF receptor
RxNorm normalized name: Toll-like receptor 9
DrugBank: Toll-like receptor 9 (DB15320)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GM-CSF receptor expression
Trial: 18286870
Drug: Antipsychotic drugs
RxNorm normalized name: Diazepines, oxazepines, thiazepines and oxepines antipsychotic drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antipsychotic drugs (long-term use)
Trial: 18286870
Drug: Highly active
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Highly active antiretroviral therapy (HIV control group)
Trial: 16545330
Drug: Stediril 30
RxNorm normalized name: ropivacaine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Stediril 30 (oral contraceptive containing levonorgestrel)
Trial: 11261274
Drug: High-dose consolidation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose consolidation therapy
Trial: 6282024
Drug: Captopril (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (200 mg)
Trial: 29394175
Drug: Sequential combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential combination of low‐ and high‐frequency stimulations (n = 8)
Trial: 27032884
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin type A (BTX‐A) injection after ESD
Trial: 24395980
Drug: Not treated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Not treated with β-blockers
Trial: 21383686
Drug: Upfront therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Upfront therapy for aGVHD
Trial: 21383686
Drug: No response
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No response to therapy by day 28
Trial: 25061313
Drug: Aliskiren-based therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aliskiren-based therapy
Trial: 17464949
Drug: High-dose ifosfamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose ifosfamide (12 g/m(2)/cycle)
Trial: 17464949
Drug: Standard-dose ifosfamide
RxNorm normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard-dose ifosfamide (6 g/m(2)/cycle)
Trial: 8730122
Drug: rIFN-gamma 0.01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rIFN-gamma 0.01 mg/m2/day for 1 week, followed by 0.1 mg/m2/day intramuscularly for 18 weeks
Trial: 7091876
Drug: Cimetidine (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (300 mg orally)
Trial: 21239519
Drug: Transdermal testosterone
RxNorm normalized name: testosterone Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal testosterone (10 mg) with GH (0.6 mg/d)
Trial: 21239519
Drug: Oral testosterone
RxNorm normalized name: testosterone Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral testosterone (40 mg) with GH (0.6 mg/d)
Trial: 21239519
Drug: GH therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH therapy alone
Trial: 21239519
Drug: Transdermal testosterone
RxNorm normalized name: testosterone Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal testosterone (10 mg)
Trial: 21239519
Drug: Oral testosterone
RxNorm normalized name: testosterone Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral testosterone (40 mg)
Trial: 12528101
Drug: Adalimumab 20
RxNorm normalized name: ADALIMUMAB 20MG/0.4ML INJ SYRINGE KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adalimumab 20 mg plus MTX
Trial: 12528101
Drug: Adalimumab 40
RxNorm normalized name: ADALIMUMAB 40MG/0.8ML INJ,PEN,KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adalimumab 40 mg plus MTX
Trial: 12528101
Drug: Adalimumab 80
RxNorm normalized name: ADALIMUMAB 80MG/0.8ML INJ PEN KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adalimumab 80 mg plus MTX
Trial: 8899499
Drug: IFN-alpha, 16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFN-alpha, 16 million U1 intramuscularly daily for 2 weeks, then three times a week
Trial: 8899499
Drug: IFN-alpha, 24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFN-alpha, 24 weeks treatment
Trial: 8899499
Drug: IFN-alpha, 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFN-alpha, 40 weeks treatment
Trial: 8899499
Drug: IFN-alpha, long-term
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFN-alpha, long-term treatment
Trial: 8899499
Drug: IFN-alpha, treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFN-alpha, treatment for HCV-RNA genotype 1b and 2a or 2b
Trial: 8899499
Drug: IFN-alpha, 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFN-alpha, 40 weeks treatment for patients with mild liver tissue damage or low virus counts
Trial: 2056598
Drug: 11 ml
RxNorm normalized name: camphor 0.11 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 11 ml 2% lidocaine jelly
Trial: 2056598
Drug: 20 ml
RxNorm normalized name: Exact-Med, 20 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 ml 2% lidocaine jelly
Trial: 27864694
Drug: Bevacizumab (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab (15 mg/kg every 3 weeks for the first 6 of 8 cycles and for 10 doses postoperatively)
Trial: 22533496
Drug: Bedtime dose
RxNorm normalized name: Buckley's Bedtime Formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bedtime dose of ARB
Trial: 22533496
Drug: Morning dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morning dose of ARB
Trial: 18708615
Drug: Ruboxistaurin (RBX)
RxNorm normalized name: ethanol
DrugBank: Ruboxistaurin (DB11829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ruboxistaurin (RBX) 32 mg/d
Trial: 17575470
Drug: 12‐week treadmill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12‐week treadmill exercise program (target lactate 2.5 +/‐ 0.5 mmol/l)
Trial: 15735183
Drug: Continuous subcutaneous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous subcutaneous insulin infusion (CSII) with insulin aspart
Trial: 15220227
Drug: Multiple daily
RxNorm normalized name: Multivitamin Oral Tablet [MULTIPLE DAILY W/BETA]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple daily injections (MDI) with once-daily glargine and premeal/snack insulin aspart
Trial: 21169170
Drug: 8-week therapist-assisted
RxNorm normalized name: milnacipran
DrugBank: Milnacipran (DB04896)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 8-week therapist-assisted Web-based treatment
Trial: 17711615
Drug: Case formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Case formulation (CF) in cognitive behaviour therapy
Trial: 14616330
Drug: Ondansetron 4
RxNorm normalized name: ondansetron 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron 4 mg IV (O4)
Trial: 14616330
Drug: Ondansetron 8
RxNorm normalized name: ondansetron 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron 8 mg IV (O8)
Trial: 10819278
Drug: Low-dose aprotinin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose aprotinin (500,000 KIU)
Trial: 10819278
Drug: Medium-dose aprotinin
RxNorm normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medium-dose aprotinin (1,000,000 KIU load, 250,000 KIU/hr infusion)
Trial: 10819278
Drug: High-dose aprotinin
RxNorm normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High-dose aprotinin (2,000,000 KIU load, 500,000 KIU/hr infusion)
Trial: 10819278
Drug: Aprotinin (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aprotinin (all doses combined)
Trial: 9087576
Drug: Cold crystalloid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cold crystalloid cardioplegic solution
Trial: 9087576
Drug: Cold blood
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cold blood cardioplegic solution
Trial: 8442967
Drug: Epidural morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural morphine (2 mg diluted in 10 ml saline)
Trial: 8442967
Drug: Epidural lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural lidocaine (10 ml of 2% lidocaine)